文献速递肿瘤 PET/CT核素与放射性配体治疗

基线全身病灶糖酵解能否提升NCCN-IPI对原发性胃弥漫大B细胞淋巴瘤接受R-CHOP方案患者的预后价值

Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
PubMed 文献 · Clin Nucl Med · 2021-01-01

随访5-108个月,高TLG和高NCCN-IPI均与不良PFS和OS显著相关,且均为独立预测因子;两者联合可将患者分为高危、中危、低危三组,PFS和OS差异均有统计学意义(P<0.001),改善风险分层。

要点

  • 高TLG和高NCCN-IPI是PFS和OS的独立不良预测因子。
  • TLG联合NCCN-IPI可将患者分为三组,PFS和OS组间差异显著(P<0.001)。
  • 联合分组中高危组PFS 57.7%、OS 61.5%,低危组PFS 97.6%、OS 100.0%。

核心结论

  • TLG和NCCN-IPI均为PG-DLBCL患者生存的独立预测因子。
  • TLG与NCCN-IPI联合可改善患者风险分层,可能有助于个体化治疗方案。

研究设计与样本

  • 对FDG高摄取病灶进行分割,计算SUVmax、TMTV和TLG,以PFS和OS为终点评估预后。

主要发现

  • 随访5至108个月(35.3 ± 23.5个月)期间,高TLG和高NCCN-IPI与不良PFS和OS显著相关。
  • TLG和NCCN-IPI是PFS和OS的独立预测因子。
  • 联合分组:高危组(TLG > 1159.1且NCCN-IPI 4-8,n=42)PFS 57.7%、OS 61.5%;中危组(TLG > 1159.1或NCCN-IPI 4-8,n=26)PFS和OS均为76.9%;低危组(TLG ≤ 1159.1且NCCN-IPI 0-3,n=26)PFS 97.6%、OS 100.0%;组间PFS和OS差异均P<0.001。

关键数值与推荐

  • TLG阈值1159.1用于联合分组:TLG > 1159.1为高TLG,TLG ≤ 1159.1为低TLG。
  • NCCN-IPI评分4-8为高风险,0-3为低风险。
  • 联合分组:高危=TLG > 1159.1且NCCN-IPI 4-8;中危=TLG > 1159.1或NCCN-IPI 4-8;低危=TLG ≤ 1159.1且NCCN-IPI 0-3。

临床怎么用

  • 对接受R-CHOP类方案治疗的PG-DLBCL患者,可基于基线PET/CT计算的TLG联合NCCN-IPI进行风险分层。
  • 联合分层有助于识别高危患者,可能为个体化治疗决策提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim was to explore whether baseline total lesion glycolysis (TLG) can improve the prognostic value of the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) in primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients treated with an R-CHOP-like regimen. MATERIALS AND METHODS: Ninety-four PG-DLBCL patients who underwent baseline PET/CT between July 2010 and May 2019 were included in this retrospective study. FDG-avid lesions in each patient were segmented to calculate the SUVmax, total metabolic tumor volume (TMTV), and TLG. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate prognosis. RESULTS: During the follow-up period of 5 to 108 months (35.3 ± 23.5 months), high TLG and a high NCCN-IPI were significantly associated with poor PFS and OS. Total lesion glycolysis and the NCCN-IPI were independent predictors of PFS and OS. Patients were stratified into 3 groups according to the combination of TLG and the NCCN-IPI for PFS (P < 0.001) and OS (P < 0.001): high-risk group (TLG > 1159.1 and NCCN-IPI 4-8) (PFS and OS, 57.7% and 61.5%, respectively, n = 42), intermediate-risk group (TLG > 1159.1 or NCCN-IPI 4-8) (PFS and OS, both 76.9%, n = 26), and low-risk group (TLG ≤ 1159.1 and NCCN-IPI 0-3) (PFS and OS, 97.6% and 100.0%, respectively, n = 26). CONCLUSIONS: Both TLG and the NCCN-IPI are independent predictors of PG-DLBCL patient survival. Moreover, the combination of TLG and the NCCN-IPI improved patient risk stratification and might help personalize therapeutic regimens.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jiang C, Ding C, Xu J, et al. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen? Clin Nucl Med. 2021. PMID: 33181743. doi:10.1097/RLU.0000000000003378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。